Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which i...

Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Ca...

Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed to earnings Operating income2 grew by 13% at constant currency, further driving margin expansion Stable reported operating income and 20% increase in reported net income3 Operating cash flow improve...

Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.

Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, and ESG impacts, featuring profiles of key players like Johns Hopkins and Mayo Clinic. Discover market dynamics and competitive landscape strategies. Explore the latest report on the global outpatie...

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plans Profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 margins FME25+ savings target expanded by EUR 300 million...